Advertisement
Person › Details
Mondher Majhoubi (Innate Pharma S.A. (Euronext Paris: IPH, Nasdaq: IPHA))
Mahjoubi, Mondher (Innate Pharma 201612– CEO before AstraZeneca + Genentech + Aventis + Sanofi)
Organisation | Innate Pharma S.A. (Euronext Paris: IPH, Nasdaq: IPHA) | |
Product | therapeutic antibody | |
Product 2 | cancer immunotherapy (immuno-oncology, I-O) | |
Record changed: 2020-06-26 |
Advertisement
More documents for Mondher Majhoubi
- [1] PDC*line Pharma S.A.. (6/25/20). "Press Release: PDC*line Pharma Welcomes Dr. Mondher Mahjoubi as Chairman of Its Board of Directors". Liège & Grenoble....
- [2] Innate Pharma S.A.. (11/13/19). "Press Release: Innate Pharma Third Quarter 2019 Report"....
- [3] Innate Pharma S.A.. (10/23/18). "Press Release: Innate Pharma Strengthens and Expands Its Oncology Development Collaboration with AstraZeneca". Marseille....
- [4] Innate Pharma S.A.. (5/16/18). "Press Release: First Quarter 2018 Report". Marseille....
- [5] Innate Pharma S.A.. (1/30/18). "Press Release: Innate Pharma and MedImmune Enter Clinical Trial Collaboration". Marseille....
- [6] Innate Pharma S.A.. (6/2/17). "Press Release: Innate Pharma Strenghtens Its Proprietary Pipeline with the Acquisition of anti-C5aR, a First-in-class Clinical-stage Antibody from Novo Nordisk A/S". Marseille....
- [7] Innate Pharma S.A.. (1/4/17). "Press Release: Upcoming Investor Conferences". Marseille....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top